Get the Stockscreener App
21.27
0.89%
-0.19
Catalyst Pharmaceuticals Inc stock is traded at $21.27, with a volume of 1.62M.
It is down -0.89% in the last 24 hours and up +0.57% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$21.46
Open:
$21.27
24h Volume:
1.62M
Relative Volume:
1.75
Market Cap:
$2.54B
Revenue:
$434.48M
Net Income/Loss:
$68.15M
P/E Ratio:
21.06
EPS:
1.01
Net Cash Flow:
$114.96M
1W Performance:
-0.51%
1M Performance:
+0.57%
6M Performance:
+40.12%
1Y Performance:
+48.74%
1-Day Range:
$21.01
$21.41
1-Week Range:
$21.01
$22.66
52-Week Range:
$13.12
$24.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.27 | 2.54B | 434.48M | 68.15M | 114.96M | 0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Barclays PLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wellington Management Group LLP Makes New $1.19 Million Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease - Simply Wall St
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Significant Increase in Short Interest - MarketBeat
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Catalyst Pharmaceuticals to Present at JPMorgan's Prestigious Healthcare Conference 2025 - StockTitan
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by State Street Corp - MarketBeat
Jane Street Group LLC Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Janus Henderson Group PLC - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future - Seeking Alpha
Verition Fund Management LLC Buys 43,447 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Jacobs Levy Equity Management Inc. Cuts Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Down 5.5% in November - MarketBeat
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Martingale Asset Management L P Buys New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Walleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Zacks Research Has Negative Estimate for CPRX Q4 Earnings - MarketBeat
Insiders At Catalyst Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness - Simply Wall St
Intech Investment Management LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Gary Ingenito Sells 12,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells 17,500 Shares of Stock - MarketBeat
Catalyst Pharmaceuticals executive sells shares worth $272,654 By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals director Harper sells $385,000 in stock By Investing.com - Investing.com Nigeria
Catalyst Pharmaceuticals director Harper sells $385,000 in stock - Investing.com
Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock - Investing.com
Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock By Investing.com - Investing.com UK
Capstone Investment Advisors LLC Makes New $708,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
FORA Capital LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Recognized as One of North - GlobeNewswire
Segall Bryant & Hamill LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List - Yahoo Finance
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock - Investing.com India
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chairman sells $3.6 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Insider Trades Send A Signal - Benzinga
Pacer Advisors Inc. Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Miller Steve | Chief Op. & Scientific Officer |
Dec 10 '24 |
Option Exercise |
4.01 |
50,000 |
200,500 |
736,996 |
| Miller Steve | Chief Op. & Scientific Officer |
Dec 10 '24 |
Sale |
21.93 |
50,000 |
1,096,350 |
686,996 |
| O'Keeffe Charles B | Director |
Dec 10 '24 |
Option Exercise |
4.01 |
40,000 |
160,400 |
727,137 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):